Actively Recruiting
Real-World Observational Study of Trastuzumab Deruxtecan Treatment Patterns and Outcomes in Female Patients with HR-Positive, HER2-Low or Ultralow Metastatic Breast Cancer Previously Treated with Endocrine Therapy
Led by AstraZeneca · Updated on 2026-09-23
109
Participants Needed
9
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are collecting real-world data in the Gulf Cooperation Council GCC countries on patients with hormone receptor-positive HR-positive, HER2-low or HER2-ultralow metastatic breast cancer mBC who have previously been treated with endocrine therapy. The study evaluates patient characteristics, treatment patterns, survival outcomes, and the safety of Trastuzumab Deruxtecan T-DXd to help optimize treatments and improve outcomes for mBC patients in the region. This observational study follows patients who have started treatment with T-DXd as part of their routine care. Eligible participants include female patients aged 18 years or older with confirmed HR-positive metastatic breast cancer classified as HER2-low or HER2-ultralow, who have received at least one prior line of endocrine therapy but no chemotherapy in the metastatic setting. Patients are observed for up to 18 months to assess treatment patterns and safety. Participants will have their health information collected and monitored, including progression-free survival, time to next treatment, safety profiles, and baseline characteristics. Data is gathered through routine clinical visits without intervention from the study team. The study duration extends through March 2029, allowing for long-term observation of treatment outcomes and patient experiences.
CONDITIONS
Brief Title
BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Research Team
S
Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here